Market Research Logo

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015’, provides an overview of the Diffuse Large B-Cell Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Diffuse Large B-Cell Lymphoma Overview
Therapeutics Development
Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview
Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis
Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies
Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes
Diffuse Large B-Cell Lymphoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Diffuse Large B-Cell Lymphoma - Products under Development by Companies
Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes
Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development
AbbVie Inc.
Affimed Therapeutics AG
Amgen Inc.
Aprogen, Inc.
Arrien Pharmaceuticals, LLC
Astellas Pharma Inc.
AstraZeneca Plc
Aurigene Discovery Technologies Limited
Bayer AG
BIND Therapeutics, Inc.
Biocon Limited
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Cell>Point, L.L.C.
Cellular Biomedicine Group, Inc.
Constellation Pharmaceuticals, Inc.
CTI BioPharma Corp.
CureTech Ltd.
Curis, Inc.
Eisai Co., Ltd.
EpiZyme, Inc.
Erytech Pharma SA
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Idera Pharmaceuticals, Inc.
ImmunoGen, Inc.
Immunomedics, Inc.
Immunovaccine, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Johnson & Johnson
Karus Therapeutics Limited
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Mabion SA
MedImmune, LLC
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Mirna Therapeutics, Inc.
Molplex Ltd.
MorphoSys AG
Nimbus Therapeutics, LLC
Nordic Nanovector AS
Novartis AG
Ono Pharmaceutical Co., Ltd.
Onyx Pharmaceuticals, Inc.
Pfizer Inc.
Pharmacyclics, Inc.
Philogen S.p.A.
Portola Pharmaceuticals, Inc.
Priaxon AG
ProNAi Therapeutics, Inc.
RedHill Biopharma Ltd.
Redx Pharma Ltd
Respiratorius AB
Rhizen Pharmaceuticals SA
Sandoz International GmbH
Seattle Genetics, Inc.
Taiho Pharmaceutical Co., Ltd.
TG Therapeutics, Inc.
Diffuse Large B-Cell Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
187Re-EC-G - Drug Profile
490-PXN - Drug Profile
ABC-294640 - Drug Profile
acalisib - Drug Profile
ACP-196 - Drug Profile
AFM-11 - Drug Profile
AFM-13 - Drug Profile
alisertib - Drug Profile
ARN-3236 - Drug Profile
ASN-002 - Drug Profile
asparaginase - Drug Profile
atezolizumab - Drug Profile
azacitidine - Drug Profile
AZD-2811 - Drug Profile
AZD-3965 - Drug Profile
AZD-9150 - Drug Profile
bendamustine hydrochloride - Drug Profile
Betalutin - Drug Profile
BI-836826 - Drug Profile
blinatumomab - Drug Profile
BLyS-gel - Drug Profile
BMS-986016 - Drug Profile
bortezomib - Drug Profile
brentuximab vedotin - Drug Profile
buparlisib hydrochloride - Drug Profile
BVX-20 - Drug Profile
carfilzomib - Drug Profile
CBM-C19.1 - Drug Profile
CBM-C20.1 - Drug Profile
CC-122 - Drug Profile
CC-223 - Drug Profile
Cell Therapy for Oncology - Drug Profile
Cell Therapy to Target CD19 for Oncology - Drug Profile
cerdulatinib - Drug Profile
coltuximab ravtansine - Drug Profile
copanlisib hydrochloride - Drug Profile
CPI-0610 - Drug Profile
CPI-169 - Drug Profile
CUDC-427 - Drug Profile
CUDC-907 - Drug Profile
daratumumab - Drug Profile
Darleukin - Drug Profile
denintuzumab mafodotin - Drug Profile
DPX-Survivac - Drug Profile
duvelisib - Drug Profile
E-6438 - Drug Profile
E-7449 - Drug Profile
epacadostat - Drug Profile
epratuzumab - Drug Profile
everolimus - Drug Profile
GS-5829 - Drug Profile
GS-9973 - Drug Profile
GSK-2816126 - Drug Profile
ibrutinib - Drug Profile
idelalisib - Drug Profile
IMGN-529 - Drug Profile
IMO-8400 - Drug Profile
inotuzumab ozogamicin - Drug Profile
IT-901 - Drug Profile
JNJ-64052781 - Drug Profile
KA-2237 - Drug Profile
KTE-C19 CAR - Drug Profile
lenalidomide - Drug Profile
MEDI-0680 - Drug Profile
MEDI-551 - Drug Profile
MK-2206 - Drug Profile
MK-8628 - Drug Profile
mocetinostat - Drug Profile
Monoclonal Antibody to Agonize CD40 for Diffuse Large B-Cell Lymphoma and Solid Tumors - Drug Profile
MOR-208 - Drug Profile
moxetumomab pasudotox - Drug Profile
MRX-34 - Drug Profile
NBD Peptide - Drug Profile
ND-2110 - Drug Profile
ND-2158 - Drug Profile
nivolumab - Drug Profile
obinutuzumab - Drug Profile
pecazine - Drug Profile
pembrolizumab - Drug Profile
pidilizumab - Drug Profile
pixantrone dimaleate - Drug Profile
PNT-2258 - Drug Profile
polatuzumab vedotin - Drug Profile
PRT-060318 - Drug Profile
Pt-EC-G - Drug Profile
rituximab biosimilar - Drug Profile
rituximab biosimilar - Drug Profile
rituximab biosimilar - Drug Profile
rituximab biosimilar - Drug Profile
rituximab biosimilar - Drug Profile
romidepsin - Drug Profile
RP-6530 - Drug Profile
ruxolitinib phosphate - Drug Profile
selinexor - Drug Profile
SGN-CD70A - Drug Profile
SH-7129 - Drug Profile
Small Molecule to Inhibit BTK for Cancer and Autoimmune disorders - Drug Profile
Small Molecule to Inhibit IRAK-4 Cancer and Inflammation - Drug Profile
Small Molecules for Diffuse Large B Cell Lymphoma - Drug Profile
Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile
Small Molecules to Inhibit NF-kappa B for Diffuse Large B-Cell Lymphoma - Drug Profile
sotrastaurin acetate - Drug Profile
spebrutinib besylate - Drug Profile
Synthetic Peptide to Inhibit Bcl-6 for Diffuse Large B-Cell Lymphoma and Acute Lymphoblastic Leukemia - Drug Profile
TAK-659 - Drug Profile
TAS-5567 - Drug Profile
tisagenlecleucel-T - Drug Profile
ublituximab [INN] + TGR-1202 - Drug Profile
ulocuplumab - Drug Profile
urelumab - Drug Profile
valproate sodium - Drug Profile
venetoclax - Drug Profile
vorinostat - Drug Profile
Diffuse Large B-Cell Lymphoma - Recent Pipeline Updates
Diffuse Large B-Cell Lymphoma - Dormant Projects
Diffuse Large B-Cell Lymphoma - Discontinued Products
Diffuse Large B-Cell Lymphoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2015
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by AbbVie Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Aprogen, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Astellas Pharma Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by AstraZeneca Plc, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Bayer AG, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by BIND Therapeutics, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Biocon Limited, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Celgene Corporation, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Cell>Point, L.L.C., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by CTI BioPharma Corp., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by CureTech Ltd., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Curis, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by EpiZyme, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Erytech Pharma SA, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Genentech, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by ImmunoGen, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Immunomedics, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Immunovaccine, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Incyte Corporation, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Johnson & Johnson, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Karus Therapeutics Limited, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Kite Pharma, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Mabion SA, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by MedImmune, LLC, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Merck & Co., Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Mirna Therapeutics, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Molplex Ltd., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by MorphoSys AG, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Nordic Nanovector AS, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Novartis AG, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Pfizer Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Philogen S.p.A., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Priaxon AG, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by RedHill Biopharma Ltd., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Redx Pharma Ltd, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Respiratorius AB, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Sandoz International GmbH, H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015
Diffuse Large B-Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Diffuse Large B-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2015
Diffuse Large B-Cell Lymphoma - Dormant Projects, H1 2015
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..1), H1 2015
Diffuse Large B-Cell Lymphoma - Discontinued Products, H1 2015
Diffuse Large B-Cell Lymphoma - Discontinued Products (Contd..1), H1 2015
List of Figures
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2015
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report